1.
Fiedler W, Montesinos P, Schliemann C, Middeke J, Vasu S, Scholz CW, Esteve J, Mondal S, RĂ¼ter B, Burkard U, Osswald A, Blum W. An open-label, phase I/II trial to determine the maximum tolerated dose and investigate safety, pharmacokinetics and efficacy of BI 836858, an unconjugated anti-CD33 monoclonal antibody, in combination with decitabine in patients with acute myeloid leukemia. haematol [Internet]. 2022Dec.1 [cited 2024Apr.20];107(12):2977-82. Available from: https://haematologica.org/article/view/haematol.2022.281128